Cancer Center's lymphoma specialist, Dr. Palomba, provides an in-depth look at how CAR T-cell therapy is evolving to offer ...

Think of it this way — the human body is a kingdom which is healthy, prosperous and functions peacefully. Every once in a while, invaders from the pat ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

Our patients, they get CAR-T cells either in the hospital or outpatient. So, we either admit the patient for about 10 days, we give them the cells, you know, on the first day, their own cells. And ...

Chimeric antigen receptor T-cell therapy has been really instrumental in how we treat patients with myeloma. It has really changed the face of how we treat this disease, so since 2021, we've had two ...

CAR T-cell therapy showed efficacy in relapsed large B-cell lymphoma across age groups, including patients 70 and 80 years or older.

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and ...

CAR-Ts can sometimes cause cytokine release syndrome (CRS), when the immune system ... CLBR001 cells – billed as a "universal" CAR-T because they are not targeted at a specific antigen ...

Like other CAR-T treatments in development, Kymriah does carry significant safety risks. The greatest of these is cytokine release syndrome (CRS), an immune system firestorm which has proven fatal ...